Barrett's esophagus: Management and surveillance. Article seven in the series

David A Katzka, D. O. Castell

Research output: Contribution to journalArticle

Abstract

Over the past 5 years, the treatment and evaluation of Barrett's metaplasia has gone from a simple proposal of treating reflux and screening all patients equally to a complex algorithm of disease-specific treatment options and various screening protocols depending on the type of Barrett's epithelium and level of dysplasia. The essentials of today's treatments are to achieve complete elimination of gastroesophageal reflux as measured by ambulatory pH monitoring through either proton pump inhibitors or fundoplication, with an eye toward the future on techniques to ablate completely the metaplastic epithelium. The need for screening is now determined by the histologic type of Barrett's mucosa that is present, and methods of screening involve aggressive biopsy sampling of the entire length of the metaplastic epithelium, a review of dysplastic mucosa by an expert in the field, and developing new screening techniques to improve accuracy of detection and prediction of which patients may go on the develop dysplasia and carcinoma.

Original languageEnglish (US)
Pages (from-to)24-26+31
JournalPractical Gastroenterology
Volume20
Issue number1
StatePublished - 1996
Externally publishedYes

Fingerprint

Barrett Esophagus
Mucous Membrane
Epithelium
Ambulatory Monitoring
Fundoplication
Proton Pump Inhibitors
Gastroesophageal Reflux
Therapeutics
Carcinoma
Biopsy

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Barrett's esophagus : Management and surveillance. Article seven in the series. / Katzka, David A; Castell, D. O.

In: Practical Gastroenterology, Vol. 20, No. 1, 1996, p. 24-26+31.

Research output: Contribution to journalArticle

@article{cf50095e9be8405d83a268d29e4136f0,
title = "Barrett's esophagus: Management and surveillance. Article seven in the series",
abstract = "Over the past 5 years, the treatment and evaluation of Barrett's metaplasia has gone from a simple proposal of treating reflux and screening all patients equally to a complex algorithm of disease-specific treatment options and various screening protocols depending on the type of Barrett's epithelium and level of dysplasia. The essentials of today's treatments are to achieve complete elimination of gastroesophageal reflux as measured by ambulatory pH monitoring through either proton pump inhibitors or fundoplication, with an eye toward the future on techniques to ablate completely the metaplastic epithelium. The need for screening is now determined by the histologic type of Barrett's mucosa that is present, and methods of screening involve aggressive biopsy sampling of the entire length of the metaplastic epithelium, a review of dysplastic mucosa by an expert in the field, and developing new screening techniques to improve accuracy of detection and prediction of which patients may go on the develop dysplasia and carcinoma.",
author = "Katzka, {David A} and Castell, {D. O.}",
year = "1996",
language = "English (US)",
volume = "20",
pages = "24--26+31",
journal = "Practical Gastroenterology",
issn = "0277-4208",
publisher = "Shugar Publishing Inc.",
number = "1",

}

TY - JOUR

T1 - Barrett's esophagus

T2 - Management and surveillance. Article seven in the series

AU - Katzka, David A

AU - Castell, D. O.

PY - 1996

Y1 - 1996

N2 - Over the past 5 years, the treatment and evaluation of Barrett's metaplasia has gone from a simple proposal of treating reflux and screening all patients equally to a complex algorithm of disease-specific treatment options and various screening protocols depending on the type of Barrett's epithelium and level of dysplasia. The essentials of today's treatments are to achieve complete elimination of gastroesophageal reflux as measured by ambulatory pH monitoring through either proton pump inhibitors or fundoplication, with an eye toward the future on techniques to ablate completely the metaplastic epithelium. The need for screening is now determined by the histologic type of Barrett's mucosa that is present, and methods of screening involve aggressive biopsy sampling of the entire length of the metaplastic epithelium, a review of dysplastic mucosa by an expert in the field, and developing new screening techniques to improve accuracy of detection and prediction of which patients may go on the develop dysplasia and carcinoma.

AB - Over the past 5 years, the treatment and evaluation of Barrett's metaplasia has gone from a simple proposal of treating reflux and screening all patients equally to a complex algorithm of disease-specific treatment options and various screening protocols depending on the type of Barrett's epithelium and level of dysplasia. The essentials of today's treatments are to achieve complete elimination of gastroesophageal reflux as measured by ambulatory pH monitoring through either proton pump inhibitors or fundoplication, with an eye toward the future on techniques to ablate completely the metaplastic epithelium. The need for screening is now determined by the histologic type of Barrett's mucosa that is present, and methods of screening involve aggressive biopsy sampling of the entire length of the metaplastic epithelium, a review of dysplastic mucosa by an expert in the field, and developing new screening techniques to improve accuracy of detection and prediction of which patients may go on the develop dysplasia and carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0029871755&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029871755&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0029871755

VL - 20

SP - 24-26+31

JO - Practical Gastroenterology

JF - Practical Gastroenterology

SN - 0277-4208

IS - 1

ER -